metastatic basal cell carcinoma
Recently Published Documents


TOTAL DOCUMENTS

217
(FIVE YEARS 32)

H-INDEX

26
(FIVE YEARS 2)

2022 ◽  
Vol 13 (1) ◽  
pp. 73-76
Author(s):  
Claire Quigley ◽  
Siona Ni Raghallaigh

Basal cell carcinomas (BCCs) are among the most common non-melanoma skin cancers in the world. However, given their slowly progressive nature, metastatic BCCs are a relatively uncommon entity. Below, we discuss two separate cases of metastatic BCC that we encountered in our clinical practice. The first is the case of a 57-year-old male with a right cheek BCC and bilateral pulmonary metastases. The second is the case of a 71-year-old male who also presented with a right BCC and pulmonary metastases. We discuss their altered clinical courses. We also conducted a review of the literature focusing on the use of the relatively novel hedgehog inhibitors as a treatment option for individuals diagnosed with metastatic BCC.


2021 ◽  
Vol 79 (3) ◽  
pp. 261-264
Author(s):  
Luísa Rolim ◽  
Bruno M. Fernandes ◽  
Carolina Carvalho ◽  
António Silva ◽  
Joana Calvão ◽  
...  

Basal cell carcinoma is the most common skin cancer, with a very low incidence of metastases, associated with high morbidity and mortality. The morpheaform clinical variant is uncommon, presenting an aggressive growth pattern. Early diagnosis and new targeted therapies for metastatic disease are important to improve survival rates. We present the case of a 29-year-old patient with morpheaform basal cell carcinoma in the right genian region. Due to local recurrences, he underwent surgery and adjuvant radiotherapy. For extensive metastatic bone involvement, the patient started vismodegib and, later, pembrolizumab, and also performed palliative radiotherapy. Despite several lines of systemic therapy, the disease progressed, and the patient died after 8 years of follow-up. This case shows how crucial it is to identify risk factors for metastatic basal cell carcinoma and highlights the need to improve target therapies and tailor them to the patient’s biological profile.


2021 ◽  
pp. 1-2
Author(s):  
Aravind Reddy Kuchkuntla ◽  

Basal cell carcinoma (BCC) is the most common cancer worldwide with an estimated annual incidence of 2 million in the United States. Majority of the patients present with a suspicious skin lesion with surrounding soft tissue destruction, but distant metastasis is rare, reportedly in less than 0.05-0.1% of all cases. So far, around 350 cases have been reported with majority of metastases occurring in primary lesions of head and neck. Here, we present a patient with high-risk BCC lesion presenting with distant metastasis.


Immunotherapy ◽  
2021 ◽  
Author(s):  
Elissar Moujaess ◽  
Reine Merhy ◽  
Joseph Kattan ◽  
Anne-Sophie Sarkis ◽  
Roland Tomb

Basal cell carcinoma (BCC) is one of the most frequent and most curable tumors at its early stages. BCC rarely metastasizes and its treatment in this setting is still challenging. Hedgehog inhibitors showed an activity in advanced or metastatic disease. However, there is an unmet need for new agents. Immune checkpoint inhibitors have been assessed in melanoma and other cutaneous tumors, and very recently an anti-PD1 was approved for advanced BCC. In this paper, available data are reviewed on experimental and preclinical studies evaluating immunotherapy in BCC, as well as on the clinical evidence supporting the efficacy and safety of immune checkpoint inhibitors for advanced or metastatic BCC based on case reports, case series and clinical trials.


Sign in / Sign up

Export Citation Format

Share Document